Literature DB >> 11753904

Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature.

M Shimoda1, D G Farmer, S D Colquhoun, M Rosove, R M Ghobrial, H Yersiz, P Chen, R W Busuttil.   

Abstract

Cholangiocellular carcinoma (CCC) is a biliary malignancy that frequently presents in advanced unresectable stages. The role of liver transplantation (LT) as a surgical modality is unclear. The goal of this study is to evaluate outcomes of patients with CCC undergoing LT. A retrospective analysis of all patients undergoing LT was undertaken. Only those patients with the pathological diagnosis of CCC were included on the study. Patients were divided into two groups based on primary tumor location: extrahepatic (EH)-CCC and intrahepatic (IH)-CCC. The Kaplan-Meier method was used to calculate overall and recurrence-free survival. Log-rank analysis was used to determine the significance of prognostic variables. Twenty-five patients were identified: 9 patients with EH-CCC (5 patients, Klatskin-type; 2 patients, the middle third; and 2 patients, the distal third) and 16 patients with IH-CCC. Mean age was 47.1 +/- 10.6 years. There were 14 men and 11 women. Tumor stage was local (stages I and II; n = 9) or advanced (stages III and IV; n = 16). Overall and disease-free survival rates were 71% and 67% at 1 year and 35% and 32% at 3 years, respectively. Analysis of variables showed statistically significant improved outcomes (P < .05) for the absence of contiguous organ invasion at LT, small tumor size, and single tumor foci. This study indicates that early survival after LT for CCC is acceptable. Three-year disease-free survival is achieved in approximately 30% of patients. These outcomes can be improved by applying strict selection criteria based on prognostic variables identified in this study.

Entities:  

Mesh:

Year:  2001        PMID: 11753904     DOI: 10.1053/jlts.2001.29419

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  44 in total

Review 1.  [Liver transplantation for hilar cholangiocarcinoma].

Authors:  F Rauchfuss; F Utess; S Schüle; Y Dittmar; H Scheuerlein; U Settmacher
Journal:  Chirurg       Date:  2012-03       Impact factor: 0.955

2.  Cholangiocarcinoma.

Authors:  Prabhleen Chahal; Todd H Baron
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

3.  Liver transplantation is not indicated for cholangiocarcinoma.

Authors:  C Wright Pinson; Derek E Moore
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

Review 4.  Liver transplantation for hilar cholangiocarcinoma.

Authors:  Ricardo Robles; Francisco Sánchez-Bueno; Pablo Ramírez; Roberto Brusadin; Pascual Parrilla
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 5.  Therapeutic options for intrahepatic cholangiocarcinoma.

Authors:  Manojkumar Bupathi; Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 6.  Liver transplantation in the management of perihilar cholangiocarcinoma.

Authors:  Aliya F Gulamhusein; William Sanchez
Journal:  Hepat Oncol       Date:  2015-11-06

Review 7.  Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection.

Authors:  Amir A Rahnemai-Azar; Pallavi Pandey; Ihab Kamel; Timothy M Pawlik
Journal:  Hepat Oncol       Date:  2017-01-20

8.  Liver Transplantation for Cholestatic Liver Disease.

Authors:  James Neuberger
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

Review 9.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

Review 10.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.